Trials / Terminated
TerminatedNCT04510285
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether treatment with trastuzumab combined with pembrolizumab will improve the clearance of tumor DNA from participants' bodies after surgery.
Conditions
- Esophagogastric Tumors
- Gastric Cancer
- Gastric Tumor
- Esophageal Cancer
- Esophageal Neoplasms
- Esophageal Tumor
- GastroEsophageal Cancer
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction Tumor
- Gastroesophageal Junction Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab | Trastuzumab (8mg/kg loading dose; 6mg/kg maintenance) will be administered on day 1 of each 3-week dosing cycle (21 days). |
| DRUG | Pembrolizumab | Pembrolizumab 200 mg IV will be administered on day 1 of each 3-week dosing cycle (21 days). |
Timeline
- Start date
- 2020-08-10
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
- First posted
- 2020-08-12
- Last updated
- 2023-02-01
- Results posted
- 2023-02-01
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04510285. Inclusion in this directory is not an endorsement.